attract pure surgic afib ablat initi
outperform
initi coverag outperform rate price
target repres uniqu pure-play surgic af atrial fibril
ablat market penetr us favor reimburs
climat abil grow clip next year compani
annual inrevenu atriclip left atrial appendag occlus devic
key growth driver hybrid af ablat endeavor pois major
mileston shortli result converg trial due hr may posit
could next big catalyst stock posit stanc base
analysi complex market uniqu valu proposit
complex afib afib complex diseas whose pathogenesi well
understood preval total direct indirect cost us
year patient recent-onset af becom refractori drug within
year af beget af long-stand af difficult treat ischem
strokes/year occur due af anticoagul complianc poor
af cathet ablat cox-maz procedur gold standard afib
ablat howev open-heart on-pump procedur across board
practic cathet ablat predomin modal use account
procedures/year us howev patient requir
revis procedur within month due primarili challeng associ
energi titrat creation transmur lesion oper techniqu
set predominantli use persist perman af current
penetr rate atriclip epicardi left atrial appendag closur
devic current annual grow y/i role laa
occlus electr isol stroke prophylaxi increment reduct
af burden drive strong uptak atriclip
converg hybrid ablat data random
superior trial compar epi endo approach endocardi ablat persist
af due present hr may exist evid indic efficaci
rate difficult patient popul success converg could
open new avenu growth hybrid af ablat
hospit procedur volum us ou geographi
hiatu note af ablat elect procedur still
short-medium term model conserv estim
revenu respect
significantli consensu account current uncertainti
year price histori atricur
manufactur market
surgic solut atrial fibril
analyst certif import disclosur see disclosur
surgic af ablat continu y/i clip
atriclip main growth driver y/i clip
converg success
reimburs rate surgic af ablat remain steadi
atriclip continu key growth driver
surgic af ablat open mi continu y/i clip
converg data readout hr
converg trial result better expect
margin expans sg synergi occur earier expect
converg outcom sub-optim
coronarviru mitig
month price target deriv use multipl sale estim slight premium
aggreg med-tech univers trade expect sale pure play difficult treat therapeut segment
real competitor horizon henc believ deserv premium aggreg univers
reimburs surgic af ablat lucr well-establish howev reimburs hybrid surgic af ablat
establish singl code industri tackl converg result publish interest note
converg repres signific mileston compani histori determin larg extent growth trajectori move
current pandem creat widespread uncertainti outlook despit surgeri deferr guidelin rel
benign toward procedur admittedli wide variat procedur depend thing normal
tabl content
etiolog afib
surgeri stand-alone afib ablat
clinic implic af
stroke afib
laarol electr isol also
atrial fibril common cardiac rhythm abnorm result rapid atrial
beat beats/minut abnorm electr activ seen atria
either spontan self-termin self-propag self-mut
afib life-threaten diseas even
presenc atrial conduct abnorm human ventricl compens
still fill capac therefor make patient asymptomat henc
substanti cohort patient seek treatment undergo
diagnosi later stage diseas problem afib time
diseas get chaotic risk stroke rise exponenti age estim
patient us patient europ
sort afib annual incid afib us alon
patients/year rang preval usual estim around gener
popul age direct correl increas risk afib even
patient diagnos afib compet treatment choic rate control vs
rhythm control pharmacotherapi vs cathet ablat complic time
intervent assess success propos therapi patient
prescrib drug regimen eventu becom refractori drug therapi within year
diagnosi ablat cardiac tissu simplist speak mean burn
tissu creat dead zone interrupt abnorm electr activ wide
accept method afib manag especi patient long-stand afib
question ablat realli center tool use ablat whether catheter-
base surgical-bas howev given factor around time intervent patient
characterist durabl result physician cardiac center expertis etc market
penetr remain low estim afib patient refractori medic
therapi us undergo cathet ablat everi year
anoth undergo surgic af ablat set cardiac surgeri
impli overal market penetr rate less us outsid
us ou penetr rate much wors poor reimburs anoth
complic factor consid
atrial fibril repres final common phenotyp multipl diseas pathway
mechan incomplet understood well-known fact af beget af
passag time henc market huge one need ration factor
challeng afib manag includ
poor fundament understand genesi af therefor complic
proper assess outcom industri evolv use freedom
af defin af second endpoint variou studi still
clear idea constitut success outcom atrial rate
pre- post-procedur stroke rate qualiti life mortal
mention af life threaten af
quality-of-lif issu main challeng stroke mitig
among patient af approxim risk ischem stroke
increas patient normal sinu rhythm estim
stroke us due af cost run multi-billion
dollar even stroke mitig af numer treatment hurdl remain
one studi stroke prophylaxi afib shown origin emboli
left atrial appendag howev studi primarili autopsi second
emboli gener afib spontaneousin aortic arch left atrial
appendag etc third anticoagul usual first-lin therapi patient
risk embol stroke af set side effect anticoagul
use last year definit improv patient take
anticoagul complianc remain issu advent novel oral
anticoagul noac definit improv complianc uniform
consensu occlud left atrial appendag laa answer
stroke prophylaxi af howev remain numer issu still close
laa use transcathet approach epicardi
design rigor random trial properli assess particular technolog
yield stroke label question realli answer use
transcathet approach logist technic physician prefer issu
trial conduct far watchman devic far
convinc opinion ye bayesian statist use gener trial
technic success howev peel layer onion help
think endovascular closur laa realli provid convinc result
come point clinician requisit experi implant
use properli size devic even reimburs issu
epicardi approach best way laa closur dont know final
real-world data new anticoagul stack vs coumadin best keep
patient oral anticoagul delay laa closur much possibl given
system effect emboli mitig dont know
anti-arrhythm drug aad usual first-lin therapi treat af
usual well-toler long term given individu cardiac toxic profil
also one fundament question afib manag still open one
simpli tri control ventricular rate af patient tri get
patient sinu rhythm overal bodi evid far indic control
ventricular rate better rhythm control af patient
hospitalization/mort cost-effect perspect stroke manag
rate control use over-the-count agent like -blocker ace-inhibitor
arb might suffici time af patient becom refractori
pharmacotherapi estim af patient long-stand af
becom refractori aad question becom
treat patient
surgic intervent becom next logic choic simplist way
lesion creat cardiac tissu order interrupt pathway abnorm
circuit propag late cox-maz procedur develop
essenti laid detail step-by-step process creat variou lesion
heart total lesion essenti shown restor
patient normal sinu rhythm data set indic proper cox-maz
result patient long-stand af sinu rhythm year
problem approach open-heart procedur use sternotomi
practic patient
subsequ research formul hypothesi creat lesion insid
heart use transcathet approach would essenti build cox-maz
procedur help million cathet ablat seen widespread adopt across
world primarili rel eas use
widespread adopt cathet ablat afib poor durabl result remain
issu cathet ablat irrespect type devic use suffer
issu relat type energi use level energi input need
kill cell creat lesion cardiac tissu transmur
lesion measur final make sure proper lesion set
actual creat first place aggreg bodi evid indic
cathet ablat poor outcom patient need revis
procedur month
last year research work tri replic
cox-maz procedur close chest procedur use differ energi sourc
led interest new result come close actual cox-maz
substanti better cathet ablat problem approach still
remainth expertis requir surgic center handl
logist patient flow coordin care abil replic
lesion one type energi sourc
one new approach evalu integr cathet surgic approach
hybrid approach creat lesion insid heart outsid heart
intrigu mani level note still unresolv
rel dearth clinic data approach mani choic
ablat tool lesion set henc alway question
combin work best patient still issu constitut
true success handl logist simultan
stagger assess increment benefit procedur
final make procedur econom viabl
promis surgic af ablat
concomitant/stand-alon hybrid
mention surgic af far know shown consist
durabl result intervent compani complet
portfolio product includ differ energi sourc ablat test
conduct block fact atricur synergi isol bipolar rf clamp devic
specif pma label treat afib compani tool use
multitud set current trial way hope shed quantit
light abil surgic af approach treat long-stand non-paroxysm
afib usual hardest treat moreov compani atriclip laa closur devic
offer rel user-friendli less-techniqu sensit way close laa either
epicardi thoracoscop sure clinic trial need get therapi
label someth like atriclip howev beauti devic view
almost immedi elimin need anticoagul unlik endovascular
approach moreov rel system side effect like
approach oral otherwis estim atriclip current use
cases/year world-wide us acquisit ncontact
provid tool target emerg hybrid stand-alon af ablat
segment finish enrol follow-up converg pivot studi
hybrid af ablat converg superior studi random compar
epicardi endocardi ablat endocardi ablat persist long-standing
persist af patient studi success could pave way new approach
surgic af ablat tap cathet market also note devil
detail compani commentari hybrid procedur
perform current pale comparison total avail market us
henc product portfolio offer differ way tackl
hardest-to-treat afib case rel cost-effect manner
target market atricur product tailor toeither af concomit
cardiac surgeri aortic valv mitral valv surgeri cabg stand-alon
chronic symptomat af prior fail cathet ablat patient comorbid
high embol risk requir thorough lesion set creationar rel
small compar overal afib popul howev excit thing
approach end-market significantli under-penetrated abil cross-
sell product within case larg preval patient rise
exponenti exampl stand-alon af patient us
refractori drug patient get sort
cathet ablat perform patient come back revis
procedur within year concomit side estim roughli
patient undergo valv surgeri concomit af nearli
patient undergo cabg surgeri coronari arteri bypass graft everi year
concomit af impli market surgic af set
concomit surgeri tune hundr thousand patients/year compar
estim case surgic af done concomit surgeri set
around per year stand-alon basi fewer
ou number look even wors anoth way state total
address market surgic concomit af market seem
penetr us penetr ou revenu
opportun signific runway ahead besid overal market
opportun favor reimburs environ along therapi label one
rf clamp help make specif sale pitch surgeon
contend signific opportun ahead grow four
way greater awar benefit surgic af minim invas manner
overal market growth cross-sel tool within case order increas
util tap stand-alon persist af opportun depend
converg trial result revenu run rate estim
less share us avail opportun atriclip product
view could game-chang catalyst clinic trial eventu showcas benefit
stroke mitig time current reimburs environ poor
outcom cathet ablat stand-alon approach long-stand af
provid structur tailwind someon like argu long-stand af
well-serv catheter-bas approach data show atricur
surgic approach closest thing surgic cox-maz possibl seem
best bridg two approach roughli sale estim
project forward compound-annual-growth-rate significantli under-penetrated market
opportun contend stock attract current level
remain pure-play surgic af uniqu complementari asset larger
strateg acquir henc strongli posit view fundament price
target deriv use multipl estim sale multipl line
aggreg med-tech univers
note initi transmed outperform cardiac system
base oh develop market product surgic ablat
long-stand atrial fibril compani isol synergi rf ablat clamp
devic pma approv ablat cardiac tissu treatment
persist sustain beyond seven day last less seven day
necessit pharmacolog electr cardiovers long-standing persist af
continu af greater year durat patient undergo open
concomit coronari arteri bypass graft valv replac repair
compani employ roughli offic locat us europ global
sale forc consist roughli repres direct sale forc
countri distributor model countri current annual
global sale grow year/year grow incid afib
better sale rep product engag random trial final grow
accept surgic af technolog especi left atrial appendag closur bode
well like
atricur product portfolio compris instrument design provid appropri lesion
set surgic minim invas epicardi set product includ
synergi clamp standard long-jaw clamp form util bipolar rf dual
electrod altern overlap field form lesion middl
surfac clamp design maintain consist pressur electrod
align across entir length jaw goal uniform lesion
creation across jaw synergi bipolar devic util dynam monitor
algorithm measur tissu respons rf deliveri time per second
system respond specif tissu properti adjust energi output time
accordingli result custom-mad column shape lesion specif tissu
length width composit rf clamp depend configur list
price roughli understand isol clamp use
isol synergi endo clamp base core synergi bipolar rf
technolog along choic right left curv jaw endo clamp
clearanc ablat cardiac tissu surgeri
coolrail linear pen steril single-us electrosurgeri devic intend ablat
cardiac tissu use bipolar rf energi coolrail pen design achiev full-
thick lesion way patent intern cool irrig electrod system
draw heat away tissu electrod circul flow
keep electrodes/tissu surfac cool enough drive energi tissu
creat robust lesion atricur line pen list price roughli
bipolar rf pen clearanc ablat cardiac tissu evalu
conduct block intern isol linear pen clear ablat cardiac tissu
temporarili pace sens record stimul evalu cardiac
exhibit order atricur isol multifunct cryoic probe
cryoic ablat probe clear use cryosurg treatment
cardiac arrhythmia cryoic devic clear treatment
cardiac arrhythmia use cryoic cryo probe list
price roughli howev usag cryo probe especi exact
replic cox-maz iv lesion clear lesion set creat
wide accept differ type energi deliveri use creat
lesion estim roughli procedur us use
cryoprob along synergi isol clamp intern
cryoic devic clear treatment cardiac arrhythmia
perhap interest devic view atriclip left atrial
appendag occlus devic atriclip laa exclus indic
occlus left atrial appendag direct visual conjunct
open cardiac surgic procedur ou atriclip clearanc occlus
left atrial appendag atriclip list price roughli
understand atriclip use almost surgic af ablat case
acquisit ncontact surgic ad epi-sens
coagul visitrax product portfolio product ce mark
approv europ coagul cardiac tissu treatment atrial
fibril atrial flutter epi-sens devic facilit multidisciplinari approach
util cardiac signal sens record ablat epicardium
atrium ventricl devic design hybrid use surgeon ep
cardiac ablat procedur addit embed sens electrod indic
epi-sens contact cardiac tissu ensur heat element
certain difficult-to-reach spot direct heart
cannula allow surgeon direct visual ablat posterior
heart without handl heart creat long linear epicardi lesion posterior
elimin need ep extens endocardi ablat posterior
access heart diaphragm need chest incis elimin
subtl access creat physician use cannula enabl truli close
chest endoscop approach episens current undergo head-head
comparison cathet ablat converg trial long-
august enter definit agreement acquir california-bas
sentreheart up-front cash mileston payment
lariat close laa remot deliv pre-ti sutur loop precis
base laa immedi complet closur procedur perform use
non-invas imag includ fluoroscopi x-ray ultrasound refer trans-
esophag echocardiographi unlik laa closur devic lariat leav
noth insid heart within month closur lariat
laa disappear never sourc blood clot compani
technolog current studi amaz trial fda-approv prospect
multicent random control trial evalu lariat sutur deliveri devic
laa closur adjunct pulmonari vein isol pvi cathet ablat
treatment persist long-standing persist afib object amaz
trial demonstr lariat devic laa closur plu pvi ablat
lead reduc incid recurr afib compar pvi alon high safeti
profil amaz trial expect enrol total patient site
one-year follow-up primari endpoint measur freedom episod afib
greater second one-year post treatment
afib
af common sustain dysrhythmia adult occur structur
and/or electrophysiolog abnorm alter atrial tissu promot impuls format
and/or propag end result irregular rhythm atria sometim
beats/min abnorm root caus af caus
divers pathophysiolog mechan af repres final common
phenotyp multipl diseas pathway mechan incomplet
understood af may occur associ arrhythmia atrial flutter
unlik flutter one wave re-activ atria fibril multipl wave
activ simultan activ atria chaotic fashion
multipl wave appear atria activ high rate almost
continu atria activ via differ path beat atrial
activ look disorgan activ often call fibrillatori wave
atria activ irregular way av node ventricl activ
irregular fashion also therefor anoth ecg featur af irregular rhythm
irregular rr interv electr activ move randomli depolar
next tissu find readi process move mani direct
result muscl contract littl littl case
atria beat fast beats/min littl current depolar
ventricular myocyt result inadequ amount blood pump
ventricl therefor fatigu dizzi import note even
atria function properli due af atrial flutter ventricl still fill
capac keep suppli blood bodi af usual fatal although
ventricular fibril
exhibit order atrial fibril patient discharg arrhythmia us
www cdc gov drbernalneurologo net journal american colleg cardiolog volume
clinic classif af
numer classif af propos base ecg present
other epicardi endocavitari record non-contact map atrial electr
activ none fulli account aspect af compound factor
comparison studi pattern af chang time acc/aha
guidelin defin variou af base complex criteria af first detect
whether symptomat self-limit recogn uncertainti
durat episod previou undetect episod main classif
episod symptomat asymptomat self-limit persistentrecurr afib episod last secondsparoxysm afib recurr af end spontan episod may last anywher second day condit ectop foci around pulmonari vein persist afibaf sustain beyond day requir pharmacotherapi cardiovers termin may episod recurr af occur episod arrhythmia convert back sinu rhythm spontan kind af random macro re-entri circuit perman potenti
categori af mutual exclus also secondari af
happen set ami cardiac surgeri pericard myocard etc break-up
paroxysm af chronic af persist perman shown exhibit
af natur progress disord initi self-termin af
becom chronic year becom year
exhibit af broken classif symptomat us
incid preval af
preval af estim gener popul estim
american roughli patient europ sort af preval
well incid increas age vast major patient older
year age shown exhibit incid af us new
patients/year distribut af age rather interest one across almost
studi shown af incid increas age sever studi
examin relationship gender af major studi publish
date suggest preval af higher men women
atria studi exampl af commonli report men vs
 framingham heart studi men af women
slightli lower preval framingham heart studi report also
document increas risk af among men benjamin colleagu report
adjust age risk factor risk develop af time
higher men women decad advanc age odd ratio
af higher men women absolut lifetim risk develop af
slightli higher men women overal risk rel compar
men women regardless age
exhibit af preval broken classif symptomat us progress af
feinberg wm intern cleveland clinic journal icin volume suppl juli radcliff cardiolog
data nhds/nch sourc circul case includ af
primari discharg diagnosi found follow
incid men rang per peopl per year patient
year age per peopl per year patient
year age older
women incid rang per peopl per year patient
year age per peopl per year
older
analysi perform california healthcar administr databas racial
variat incid af found adjust af risk factor
compar white counterpart lower incid rate found black hr
asian hr ci year observ
framingham heart studi age-adjust preval
incid af approxim quadrupl howev af
ascertain ecg routin collect framingham studi consid
preval incid increas suggest part chang
epidemiolog attribut enhanc surveil although preval
risk factor chang time hazard associ specif risk factor
exhibit order incid af gender overal chang incid incid coexist arrhythmia
burden af
key complic due af stroke death hospit present
enorm burden healthcar system data nhds/nch case
includ af primari discharg diagnosi found follow
approxim patient male
mean age male year versu year femal
rate af hospit male rang per peopl per
year patient year age per peopl per
year patient year older
rate af hospit femal rang per peopl per
year patient year age per peopl per
year older
hospit af first list diagnosi increas
basi medicar market scan databas annual individu af
approxim twice like hospit age- sex-
exhibit order hospit death due af per patient us
camm aj american journal cardio logi volume chugh et al circul
cost associ af
heart diseas stroke statist public investig make
refer medicar analysi wherein annual increment cost
af patient vs control group increment per-
patient cost extrapol us popul estim
increment cost af billion billion attribut af
billion cardiovascular expens billion non-cardiovascular
exhibit death due conduct abnorm per patient us
etiolog af
commonli observ anatom chang af atrial fibrosi loss
atrial muscl mass patchi fibrosi juxtapos normal atrial fiber caus non-
homogen conduct insuffici clinic evid exist whether fibrosi
due af af due fibrosi concentr membrane-bound glycoprotein
regul cell-cel cell-matrix interact human atrial myocardium
report doubl af increas disintegrin metalloproteinas activ may
contribut atrial dilat patient long-stand af
cmaj septemb volume
atrial fibrosi may caus genet defect like lamin ac gene mutat due
trigger inflamm cardiac sarcoidosi autoimmun disord
fibrosi trigger atrial dilat type heart diseas associ
af includ valvular diseas hypertens hf coronari atherosclerosi stretch
myocyt activ sever molecular pathway includ renin-angiotensin
aldosteron system angiotensin ii transform growth factor tgf
upregul respons stretch molecul induc product
connect tissu growth factor ctgf atrial tissu patient undergo open heart
surgeri shown amount angiotensin ace convert enzym
exhibit re-entr circuit theori af
cmaj septemb volume
sever mechan pathogenesi af propos
spontan activ ectopi foci singl re-entri circuit multipl function re-
entri circuit contemporari theori af pathogenesi requir understand
mechan arrhythmogenesi re-entri disord impuls
format impuls propag occur impuls travel around abnorm
circuit respect exhibit sinu impuls activ area
prematur beat aris area fail reach area interven tissu
remain refractori preced sinu beat prematur stimulu travel slowli
via altern rout back area allow enough time recov
excit area re-excit area cycl sustain sustain re-entri occur
area re-excit thu re-entri requir
appropri time stimulu trigger abl find way substrat
depolar wavefront encount refractori tissu anatom re-entri boundari
circuit physic cardiac structur
altern variat electrophysiolog properti contigu tissu
anatom obstacl may serv boundari function re-entry circuit
function re-entri seem import af sever model function re-
entri propos lead circl model suggest function re-entri
circuit natur occupi smallest possibl circuit size wavelength given
conduct veloc size circuit distanc travel shortest time
requir refractori tissu recov wavelength mean conduct veloc
refractori period circuit size could possibl smaller wavelength
would requir depolar wavefront collid refractori tissu
extinguish lead end circl bite tail
popular theori held af consist multipl wavelet function re-entri
stabil model deriv critic number wavelet travel
throughout atria collid combin divid therebi spawn daughter
wavelet perpetu process condit increas atrial size decreas
wavelength decreas conduct veloc refractori period permit
multipl wavelet promot af result map studi anim
human consist presenc multipl re-entr wavelet
propag differ direct although model function re-entri includ
spiral wave model propos multipl wavelet hypothesi
domin contemporari think mechan af map studi
variou model af yield differ observ limit
map resolut proof one model remain elus
pulmonari vein pv frequent sourc rapidli fire
impuls foci also found superior vena cava coronari sinu ligament
marshal etc experiment studi shown atrial tissu around
pv shorter refractori period control patient part atria
presenc fibrosi atria caus spontan termin circuit
may help stop af cardiovers howev relationship
presenc fibrosi af trigger exactli clear caus
import point note atrial refractori increas age men
women concurr age-rel fibrosi lengthen effect intra-atri conduct
pathway coupl shorter wavelength reentrant impuls increas
likelihood af develop degre atrial architectur contribut
initi mainten af also known
foci trigger
landmark paper publish identifi muscular sleev pulmonari
vein sourc tachyarrhythmia atrial prematur beat could trigger
paroxysm af later determin patient frequent paroxysm af
muscular sleev pulmonari vein display electrophysiolog properti
includ shorter refractori period distinct adjac left atrial
muscl muscular sleev pulmonari vein control subject without af
special conduct cell pulmonari vein also discov although
atrial tissu muscular sleev cardiac vein includ coronari
sinu vein marshal superior vena cava implic sourc
tachyarrhythmia af trigger beat none nearli frequenc
pulmonari vein demonstr focal tachyarrhythmia patient
paroxysm af challeng multipl wavelet hypothesi
compet theori suggest focal tachyarrhythmia may sole underli
rhythm drive af canin af model morillo colleagu demonstr
presenc tachyarrhythmia origin pulmonari vein region faster
part atria respond cathet ablat anim
model electroanatom optic map demonstr complex wavefront
within eman pulmonari vein thu focal discharg may simpli
trigger multipl wavelet re-entri rel contribut two compet
mechan explain af popul without structur heart diseas
remain larg unknown anim model persist af suffici rapid
atrial pace impli signific relationship focal driver pace
develop af thu unifi theori focal tachycardia origin
mostli around pulmonari vein promot atrial remodel requir
trigger maintain substrat capabl multipl wavelet re-entry
exhibit pv trigger af
af capabl induc electrophysiolog chang promot af collect
call atrial remodel cardiac myocyt excit rest membran
potenti polar mv becom depolar inward rush
posit charg ion action potenti begin inward calcium current caus
membran potenti plateau contribut significantli action potenti
durat rapid atrial rate period fibril repeat
intracellular calcium concentr toxic adapt mechan rapidli reduc
load protect cell earli remodel process membran channel
respons calcium entri becom less activ
eventu product channel downregul chang ultim
reduc inward calcium current turn reduc action potenti durat
action potenti durat shorten refractori period shorten cell
readi reactiv earlier henc adapt mechan respond
intracellular calcium load ultim shorten atrial refractori period promot
function re-entri perpetu af even case prolong af atrial
electr remodel revers quickli complet sinu rhythm restor
persist af recoveri atrial contractil function delay week day
follow restor sinu rhythm import implic durat
anticoagul cardiovers
atrial electrophysiolog chang induc af may widespread
effect myocyt function exampl myofila slide cellular action
respons muscl contract intim depend upon intracellular calcium
concentr studi conduct anim human demonstr af-
relat reduct atrial contractil function lessen treatment
calcium-channel antagonist exagger treatment calcium-channel agonist
suggest abnorm calcium handl high rate may respons
remodel af also result differenti myocyt fetal form cell
architectur display reduc contractil element higher resist calcium-
induc cell death thu chang associ af contribut develop
atrial cardiomyopathi
exhibit action potenti durat af
cmaj septemb volume
frequent coexist af heart failur expand focu atrial
myocardium profibrillatori chang includ conduct slow associ
scar fibrosi increas atrial size refractori period actual
proper understand treatment algorithm af import assess
total avail market opportun precis algorithm
exhibit depict rough flowchart consider variou therapi manag
afib discuss specif releg patient symptomat sinc
asymptomat patient either undiagnos usual seek treatment unless
situat absolut requir consider market size
assess
fundament decis point afib manag remain better let patient
sinu rhythm focu ventricular rate control lack
univers accept explan pathogenesi afib re-entr circuit
maintain perpetu time result research conduct
signific focus maintain ventricular rate control get
patient necessarili back sinu rhythm ye lack sinu rhythm primarili
qualiti life issu henc remain school thought long
ventricular rate control patient suffici anticoagul manag
stroke risk treatment good enough depend patient symptomat
medic taken durat af etc clinician might simpli prescrib
blocker angiotensin receptor blocker arb ace-inhibitor order lower
sympathet tone ventricular rate latest hrs/acc/aha/esc guidelin
make recommend rate control strategi within paradigm afib
year variou trial conduct determin impact rate
control vs rhythm control strategi patient afib complet descript
trial baselin patient characterist beyond scope report note
though meta-analysi five key trial affirm race piaf staf hot
caf systemat review perform explor desir rate
control vs rhythm control patient persist af outcom assum
rhythm control activ treatment rel risk reduct number need
treat per year respect clinic outcom calcul overal patient
analyz meta-analysi conclus also surprisenam
reduc risk hospit non-inferior endpoint favor rate
control less costli strategi symptom af problem
author conclud treatment target optim rate control
anticoagul therapi -blocker effect calcium channel blocker
-blocker combin digoxin seem provid better clinic outcom
rate control therapi rhythm control drug suffer signific advers side effect
limit use treat af
pharmacotherapi rhythm control
anti-arrhythm drug usual first line therapi afib manag almost
patient initi prescrib particular aad depend type af clinic
usual best recent onset af longer durat af lower
chanc convers sinu rhythm convers higher chanc signific
side effect purpos report delv current bodi
clinic evid aad interestingli enough random
control clinic trial conduct mention kind toward
rhythm control agent outcom compar use rhythm control rate
control strategi patient af rhythm control strategi fail show
superior rate control strategi compar head-to-head rhythm control
strategi shown superior mortal shown wors
term hospit cost-effect therefor routin use aad
warrant patient
although initi rate-control strategi reason mani patient sever
mainten associ improv symptom qualiti life
patient persist symptom associ af remain compel indic
rhythm-control strategi factor may favor attempt rhythm control
includ difficulti achiev adequ rate control younger patient age tachycardia-
mediat cardiomyopathi first episod af af precipit acut ill
patient prefer af progress paroxysm persist mani patient
subsequ result electr structur remodel becom irrevers
time reason accept af perman patient may render futur
rhythm-control therapi less effect may relev younger patient
wish remain candid futur develop rhythm-control therapi
market pharmacotherapi
start point market size assess ratio patient unrespons
eventu becom refractori antiarrhythm drug therapi estim
roughli patient us approxim million peopl ou suffer af
first-lin therapi patient drug therapi whether rate control rhythm
control sinc af beget af consid poor understand mechan
af prescript usual increas cocktail drug bring differ
side effect moreov patient complianc becom signific factor outcom
assess time patient becom refractori one
aad use aad also complic comorbid hypertens
heart failur coronari heart diseas etc approxim market distribut use
aad patient refractori pharmacotherapi shown exhibit
next page estim overal market pharmacotherapi us rate control
rhythm control oral anticoagul somewher billion rang oral
anticoagul grow fastest clip around growth oral
anticoagul fuel strong result direct thrombin inhibitor
factor xa agent growth rhythm control drug low-singl digit given
problem cardiac toxic patient complianc long-term refractori drug
use stand-alon ablat use cathet surgic af ablat estim
roughli billion rang us cathet ablat fastest growth
defin stand-alon cathet afib ablat market first-lin therapi
rhythm control agent exhaust patient prime candid
paroxysm af suspect pulmonari vein trigger final patient
symptomat enough want seek treatment us estim total patient
pool market symptomatic/refractori aads/pvi trigger roughli
rang ou probabl least twice number term market
penetr estim roughli cathet ablat
perform everi year us therefor make market penetr
ou market roughli patient estim number
cathet ablat rang impli penetr rate
defin market one wherein either patient undergon earlier cathet
ablat therapi fail convert sinu rhythm comorbid
necessit aggress approach surgic cox-maz stratifi
market paroxysm persist perman af believ
surgic af thoracoscop around us ou best
estim minim invas af ablat procedur done us around
overal ou around overal would essenti translat
roughli share us ou bear mind analysi
base reason estim could find base field check also
market share stand-alon side includ procedur cathet
ablat wherein denomin probabl million patient state
otherwis stand-alon surgic af procedur volum us seem around
penetr ou less penetr
incid af concomit aortic valv surgeri roughli
procedur us concomit af ablat conduct
simultan ou estim penetr rate concomit af less
mitral side incid concomit af around roughli
procedur us ou procedur treat concomit af
cabg side estim incid concomit af
us procedur ou procedur treat surgic af
ablat market share indic overal procedur current
conduct share us ou share around
perspect surgic concomit af market seem
penetr us penetr ou
snapshot market analysi shown next exhibit
exhibit order approx market size afib annual growth rate us total ablat market
exhibit order current cardiac surgeri procedur volum incid concomit af stratifi geographi actual
incid pre-op af
approx penetr af ablat surgic set
approx procedur volum open heart af ablat
exhibit order preval stand-alon af symptomat stand-alon af stratifi geographi type af stand-
alon procedur suitabl cathet ablat suitabl surgic af
symptomat stand-alon af refractori aad
stand-alon af suitabl cathet ablat pvi
stand-alon af suitabl surgic ablat
surgeri stand-alon af
cox-mazeth basi surgic af treatment
surgeri afib whether done epicardi outsid heart endocardi insid
heart part involv three key thing
incis creation lesion atria interrupt macro re-entr circuit
creation blind alley atrial electr activ
creation surgic lesion base earli studi done open-heart
procedur dr jame cox washington univers school medicin name
make linear lesion right left atria prevent occurr multipl
macro re-entr circuit thought process appropri place atrial
incis interrupt conduct rout common re-entr circuit
also direct sinu impuls surgic ablat node av node
exhibit lesion pattern cox maze surgeri
two subsequ modif cox-maz surgeri becam
standard techniqu allevi af open-heart surgic procedur cox-maz
also known cut-and-sew maze reason altern almost
patient af healthi enough open heart procedur
howev complex procedur adopt limit perform either
alon concomitantli mitral valv open-heart surgeri studi
shown littl differ success rate open-heart lone
concomit procedur success rate cox-maz procedur depend
mani factor includ classif af length time patient
af one studi conduct divis cardiothorac surgeri washington
univers school medicin st loui patient recurr atrial
fibril year surgeri one patient recurr atrial fibril
year patient studi normal sinu rhythm without
antiarrhythm drug none suffer stroke follow-up period overal
studi differ patient popul report success rate
cox-maz achiev make incis specif maze
configur incis set technic difficult perform concomit
open heart surgeri incis set also add length alreadi time-consum
surgeri increas certain risk associ open-heart cardiopulmonari bypass
procedur result limit use procedur lone concomit
open-heart procedur import element cox-maz surgic remov
left atrial appendag could respons low stroke rate seen patient
cox-maz iv procedur develop includ use variou energi
sourc creat atrial lesion surrog cut sew procedur variou
energi sourc includ unipolar bipolar rf cryosurgeri hifu microwav
laser clinic literatur cite dearth dose-respons studi use energi
sourc make rigor comparison almost imposs issu cite
unipolar energi sourc inabl creat transmur lesion
also caus collater damag energi sourc confin bipolar rf
overcom difficulti energi deliv within confin two
electrod jaw clamp therebi reduc collater damag sinc energi
deliveri requir use two electrod fundament issu limit lesion
set deliv beat heart mani case touch-up need
unipolar rf variat center-to-cent experi depend type
lesion surgeon experi type energi sourc patient condit
 damiano jr bailey multimedia manual cardiothorac surgeri
final mini-maz procedur also use institut evolv
cox-maz procedur get heart surgeon make three four small
incis side chest incis place surgic
instrument ablat devic endoscop allow direct visual
heart insid chest surgic ablat energi sourc use creat
conduct block isol pulmonari vein stop chaotic electr
signal disrupt heart surgeon treat ligament
marshal nerv bundl call ganglion plexi remov clamp
left atrial appendag reduc risk blood clot stroke
wide accept sort epicardi lesion creat need
mimic cox-maz lesion set oper differ sourc energi deliveri
outcom measur lack true clinic trial combin
differ accept benchmark success doesnt help field either
stand-alon surgic af ablat basic sens involv either median
sternotomi thoracotomyus multipl port make cox-maz lesion
use energi sourc consensu type energi sourc use
paramet creat lesion set power intens deliveri time energi
deliveri intermitt pace need durat f/u etc concomit af ablat
essenti impli lesion set part done concomitantli
patient oper anoth procedur whether aortic heart valv
surgeri cabg someth els
given current knowledg etiolog pathophysiolog af optim
ablat procedur arrhythmia would
isol pv perman
defin specif properti underli atrial electr substrat order
custom subsequ ablat strategi
alway creat complet transmur linear lesion allow assess gap
abl isol gap
minim invas
date neither endocardi approach surgic ablat procedur
abl meet criteria howev techniqu seem complementari
perform combin henc nomenclatur hybrid converg
procedur bear potenti overcom respect shortcom
epicardi surgic approach seem result superior transmur lesion
result long-last pv isol perman conduct block endocardi
af ablat procedur hand use multipolar cathet
electroanatom map system efficaci set guid substrat
modif ablat atrial tachycardia known occur stepwis
ablat persist af appear wide variat possibl
combin epicardi surgic transven endocardi techniqu lesion set
follow-up use hybrid converg af ablat procedur
exhibit sampl hybrid ablat lesion set
hybrid af sound appeal mani front remain challeng
date number patient underw hybrid af ablat remain
rel small especi patient persist long-standing persist
af one-year success rate aad promis
differ hybrid converg ablat strategi variou energi sourc
diverg definit success use make quit difficult
compar outcom therefor clear lesion lesion set need
best endpoint kind procedur lesion
common pv isol isol posterior wall la also
prefer target ectopi initi af frequent aris part la
ad valu gp ablat still area debat
biophys reason epicardi deliveri rf energi limit
term energi heat transfer excess heat epicardi layer
increas tissu imped reduc current deliveri thu repeat applic
energi may diminish return addit excess heat epicardi
surfac may occur deeper layer tissu cool endocavitari blood
flow act heat sink
cox-maz procedur cavotricuspid isthmu line complet line
mitral annulu thought import improv procedur success
howev one realli abl point exact import
lesion set clinic efficaci
anim model damiano et al demonstr function reinnerv within
period week concern rais reinnerv non-
uniform could creat new substrat af origin present
anoth advantag hybrid approach possibl exclud laa
site clot format eventu lead
thromboembol event patient nonvalvular af addit may
small number patient recurr af owe trigger nestl laa
could elimin exclus appendag combin
epicardi surgic endocardi approach one singl procedur make
possibl perform endocardi touch-up whenev epicardi lesion
complet transmur advantag anatom guid
touch-up lesion surgeon show cardiologist epicardi
lesion exactli locat immedi add-on endocardi lesion
alreadi deploy surgic lesion add form firm transmur lesion
organ kind procedur requir robust logist capac
cardiac surgeon electrophysiologist need room
endocardi procedur done first follow epicardi vice-versa
one argument favor epicardi first endocardi procedur later
date allow electroanatom map help identifi area lesion
transmur could give rise futur ectop foci re-entr circuit
almost case complet cox-maze-lik procedur isol
posterior wall left atrium devic like atricur synergi clamp
use endocardi approach offer flexibl atricur
converg procedur involv endocardi ablat first follow
epicardi ablat day real life epicardi ablat procedur
done day week endocardi procedur
anoth import concern perform endocardi ablat immedi
epicardi ablat rather stage later date may limit
endocardi map due edema transient injuri caus epicardi ablat
whether perform hybrid af ablat given patient rather
standard endocardi procedur remain difficult question long prospect
random trial lack current data suggest reserv kind procedur
patient persist long-stand persist af dilat la
fail endocardi approach signific complic rate seri like
effect learn curv kind procedur requir specif technic
expertis concern epicardi surgic aspect
level success ad stage procedur
priorit procedur certain surgic center especi given
cathet ablat expertis far preval surgic ablat
overal stage game especi given lack rigor random trial
hybrid af ablat strategi could driven econom advantag due
reimburs proven long-term success converg answer
question view
clinic implic af
import risk afib stroke mortal either due stroke
reason risk stroke exampl increas almost afib present vs
even adjust age longer durat afib higher risk
stroke similarli mortal rate patient afib almost doubl
patient without afib even adjust age third key impact afib remain
qualiti life although studi realli examin impact
exhibit impact afib order mortal rate adjust cumul stroke risk
phan et al annal cardiothorac surgeri volume jiang et al plo
like hybrid af note surgic af whether stand-alon concomit suffer
lack true random rigor control clinic trial henc data
present need taken within context aforement caveat
phan et al annal cardiothorac surgeri volume
studi author conduct meta-analysi avail studi compar
outcom surgic af ablat cathet ablat seven studi
deem suitabl analysi accord inclus criteria freedom af
significantli higher surgic af group cathet ablat group month
month studi endpoint follow-up period surgic af ablat procedur
differ type lesion set energi sourc oper techniqu etc similarli cathet
ablat techniqu variabl also exist across board patient baselin
characterist shown exhibit
exhibit baselin characterist meta-analysi conduct phan et al
phan et al annal cardiothorac surgeri
result studi summar exhibit specif author
note
cut sew procedur demonstr increas freedom af rel
cathet ablat short-term medium-term long-term
vat epicardi ablat procedur show absolut increas
freedom af
subgroup analysi demonstr significantli higher freedom af surgic
ablat paroxysm af show absolut increas freedom af
surgic cathet ablat techniqu least meta-analysi lower
previou report analys author conclud
probabl could due higher percentag patient previous fail
similar non-signific trend support superior efficaci surgic
ablat deliv freedom af also note
incid stroke cathet ablat specif studi note
similar rate vs
exhibit result meta-analysi conduct phan et al
phan et al annal cardiothorac surgeri
meta-analysi surgic ablat concomit mv surgeri
phan et al annal cardiothorac surgeri volume
studi author phan et al conduct meta-analysi use surgic af
ablat concomit mitral valv surgeri random control trial
util analysi nine studi patient underw procedur
involv mv surgeri surgic ablat mv sa without surgic
ablat mv group baselin characterist patient shown
exhibit
exhibit summari mv sa meta-analysi conduct phan et al
phan et al annal cardiothorac surgeri
author opin preval sinu rhythm sr short- long-term
follow-up import endpoint consid af patient henc focu
meta-analysi predominantli patient sr meta-analysi indic
number patient sr discharg significantli higher mv sa
group compar mv group vs
mv sa group also significantli higher proport patient sr
compar mv vs vs
vs
review found accept overal mortal rate rang follow-
period differ mv sa mv group
differ perman pacemak implant found surgic
ablat group compar control group mean vs
result present meta-analysi also indic signific differ
incid stroke thromboembol event favor surgic ablat
group compar control mv surgeri group mean vs
author conclud meta-analysi demonstr superior long-term
sr preval could achiev via surgic ablat addit risk
stroke thromboembol
note true random control studi perform far
evalu hybrid af ablat strategi henc result publish trial need
evalu within context converg view answer question
meantim proper assess hybrid af ablat complic patient
select level invas appropri type ablat cathet lesion set
chosen pv isol wide encircl la ablat linear lesion ablat target
fraction potenti ablat non-pv trigger rotor etc lesion set choic
whether occlud laa associ complic
measur success defin without without concomit anti-arrhythm
highlight result meta-analysi done jiang et al sourc plo one
jan stress import look result within
framework meta-analysi variou confound factor highli subject given
combin studi use analysi heterogen patient popul
differ trial designs/endpoints/intricaci meta-analysi studi
long-stand persist atrial fibril select averag histori
atrial fibril year pool proport patient
arrhythmia-fre primari endpoint pool rate sever
short-term complic success rate one-step procedur
lower stage procedur author conclud
stage approach could ultim prove safer although complic rate
rel low approach respect
recent european multicent experi stage hybrid af ablat
treatment persist long-standing persist af haywood et al ijc heart
vasculatur volume studi two stage hybrid ablat
thoracoscop unilater epicardi rf abl procedur perform
transvers obliqu sinus open blunt dissect suction
assist mono bipolar epicardi ablat perform remov
epicardi fat heparin given maintain act greater second
epicardi fat remov roof left atrium interatri
groov direct thoracoscop visual aim produc box
lesion set isol posterior left atrium four pv select
patient high score laa occlud use
atriclip eight cycl mono bipolar radiofrequ perform
use temperature-control cobra fusion ablat system cycl
 deliv tissu presence/abs left atrial posterior
wall conduct block follow ablat document intra-op
pace within isol zone post direct current cardiovers dccv
requir patient mobil day surgeri discharg
hour day postop depend center
exhibit hybrid ablat process involv initi surgic epicardi ablat stage second cathet ablat
site gap surgic ablat line roof left atrium close rf cathet lesion indic
second-stag procedur per protocol perform minimum
week follow epicardi surgic ablat allow time condit
recov non-perman section surgic ablat line three-
dimension map system use pv isol posterior wall
isol identifi ablat line close irrig rf ablat
lesion deliv contact force-sens ablat cathet addit
ablat line cavo-tricuspid isthmu mitral isthmu line ad
oper discret depend featur degre atrial
baselin patient characterist outcom studi shown next page
studi patient underw stage ablat eighteen patient
underw re-do ablat mean ablat per patient median follow-
sinc last ablat month studi particip af
recurr second antiarrhythm drug includ
antiarrhythm drug treat patient underw re-do ablat
treatment failur af recurr second antiarrhythm
drug consid patient underw least first-stag procedur
outcom persist lspaf patient significantli differ last
clinic follow sinu rhythm antiarrhythm drug
includ antiarrhythm drug
hybrid techniqu aim achiev pv isol also left atrial
posterior wall isol involv extens area left atrial posterior wall
roof region uniqu lesion set test earlier trial
exampl earlier trial like af ii highli influenti
attitud addit line ablat lesion set trial show
advantag pvi alon either complex fraction atrial electrogram
cfae ablat addit roof mitral isthmu line howev trial
exclud long-stand persist af patient isol posterior
wall roof region month af ii pvi freedom atrial
arrhythmia recurr drug follow mean ablat
patient report data seri high level long-standing
persist drug-refractori atrial fibril median month
continu af prior ablat entir cohort outcom month
freedom recurr atrial arrhythmia appear realist
advantag compar compar approach term patient
experi fact patient cohort maintain stabl
sinu rhythm last follow back persist af
differ approach hybrid af ablat make difficult compar
safeti efficaci mani differ methodolog report
literatur patient popul differ percentag paroxysm
earli stage persist af patient includ analysi result
studi report percent freedom af recurr anti-arrhythm drug
commonli percentag sinu rhythm particular time method
monitor vari use data implant loop record other
use period holter monitor complic report
given observ appear transabdomin converg
approach may lowest complic rate hybrid ablat
techniqu bilater bipolar clamp approach highest success rate
unitaler thoracoscop hybrid approach report lie
techniqu criteria
differ valu studi compar
trial hybrid ablat inclus left atrial appendag closur potenti
isol left atrial appendag may enhanc freedom arrhythmia
recurr well reduc long-term risk thromboembol event
remain proven
stroke af
af shown numer studi independ risk factor
ischem stroke pathogenesi stroke af complex isnt unifi
theori concret describ origin outcom thrombi approxim
ischem stroke us trace back af framingham heart studi
show stroke risk increas patient af rel
comorbid therebi make stroke prevent anticoagul one
cornerston af therapi risk stroke af increas significantli age go
per year stroke rate approxim per year age
contrast patient without af risk stroke goe approxim
per year around year age per year age stark
comparison complic af time
exhibit order incid stroke af risk stroke comorbid
approxim stroke occur af patient due intrins
cerebrovascular diseas cardiac sourc embol atheromat patholog
proxim aorta univers agre stroke af origin
due thromboemboli left atrial appendag stroke due
af report fatal wherea moder sever life-
debilit consequ howev ischem stroke af like
sever disabl non-af ischem stroke reason remain unknown
clinic evid suggest laa sought-aft culprit
pathogenesi cardioembol stroke af laa elong cul-de-sac line
endothelium trabecul pectin muscl thrombot materi
associ af shown frequent aris laa thrombi
encount af patient stroke without stroke patient af
thrombi believ origin almost alway laa rather atrial wall
howev thrombi reliabl detect use transthorac echo tte
transesophag echo tee reliabl detect thrombi thrombi
detect laa interv shorter hour onset af laa
structur usual multi-lob project differ plane therebi make
accur detect thrombi even problemat autopsi detect multi-
lobe laa case bi-lob appendag remain
pathogenesi thrombu laa clearli understood varieti contribut
factor thought result format thrombi start virchow triad
stasi system prothrombot diasthes could contribut thrombu format
hypothes convincingli identifi
exhibit order origin stroke emboli sever af stroke time stroke global sever stroke af
number clinic studi demonstr influenc reduc flow veloc
laa lead stasi therefor thrombu format mix
report endotheli dysfunct laa although along stasi
strong factor pathogenesi thrombi interestingli enough thrombi laa
resembl venou system especi deep vein thrombu dvt
known whether thrombi origin place travel free-float
clot attach wall laa veloc laa determin
strength contract appendag also atrial pressur risk stroke
shown increas age probabl stasi theori
propos loss contractil laa af although
conclus proven
hypertens correl preval risk factor stroke
hypothes lead atrial enlarg laa stasi mediat
ventricular dysfunct revers correl word control hypertens
factor elimin stasi proven elimin stroke af along
factor research highlight role aortic arch plaqu
widen puls pressur contributor reduc flow veloc laa must
state associ aortic diseas stasi laa clearli
understood last system and/ atrial tissu level p-select protein von
factor elev patient hypothes
contribut hypercoagul state biomark chang age
pose higher risk thrombu format import thing note
thrombu format mediat number differ factor
fluctuat time may may visibl tee therefor origin
cardioembol stroke extrem difficult pinpoint af
laa remnant left atrium develop third week gestat
smooth wall caviti develop form outgrowth pulmonari
vein laa orific left atrium diamet vari
patient patient laa locat upper pulmonari vein left
ventricl circumflex branch left coronari arteri run close laa basal
orific cardiac lymphat drainag left ventricl entri beneath laa
evid role laa anatom physiolog perspect
seem mix best
exhibit order left atrial appendag anatomi posit heart
risk stratif stroke afib base new score system develop
adopt univers call score score wide use
medic practic screen tool patient high-risk thromboembol
event stroke tia higher score higher risk stroke
screen tool associ stroke risk shown exhibit
exhibit order score anti-thrombot decis non-valvular af base hr esc
stroke mitig remain primari control strategi afib manag ye rhythm
control import affect qualiti life predominantli howev
irregular rhythm tachycardia especi af harm fatal
incid stroke risk combin greater sever ischem stroke af
led signific research optim deliveri anticoagul
manag side-effect coumadin date remain standard care stroke
manag use coumadin complic
multipl interact food drug
genet variabl metabol vitamin epoxid
requir frequent monitor inr due limit therapeut index access
exhibit tradeoff anti-thrombot therapi
novel oral anticoagul noac afib
excit new research stroke prophylaxi non-valvular af
direct thrombin inhibitor dti thrombin play central role gener
thrombu form thrombin activ factor viii xi involv
gener thrombin also activ factor xiii protein involv fibrin
cross-link clot stabil thrombin princip function convert solubl
fibrinogen insolubl fibrin also stimul platelet activ thrombin
inhibit directli indirectli bind thrombin-inhibit drug one two
three domain activ site exosit exosit fibrin-bind site
thrombin exosit serv heparin-bind domain tradit
anticoagul unfraction heparin ufh low-molecular-weight heparin
lmwh inhibit free thrombin indirect manner bind simultan
antithrombin exosit therebi form heparin-thrombin-antithrombin complex
howev heparin also simultan bind fibrin thrombin act
bridg therebi enhanc thrombin affin fibrin increas
concentr thrombin-bound fibrin fibrin-heparin-thrombin complex occupi
thrombin exosit leav activ site enzymat protect
inactiv heparin-antithrombin complex bind fibrin-bound thrombin
result thrombu growth
addit inabl neutral fibrin-bound thrombin limit heparin
includ bind variou plasma protein creat unpredict dose-depend
anticoagul respons need routin dose-adjust anticoagul monitor
heparin-induc thrombocytopenia hit direct thrombin inhibitor bind directli
thrombin requir cofactor antithrombin exert effect dti
inhibit solubl thrombin fibrin-bound thrombin key advantag
includ predict anticoagul effect compar heparin
lack bind plasma protein anti-platelet effect absenc
long-term use dti evalu three larg phase
random control trial apixaban reduct stroke
thromboembol event atrial fibril aristotl trial random
evalu long-term anticoagul therapi reli trial rivaroxaban
daili oral direct factor xa inhibit compar vitamin antagon
prevent stroke embol trial atrial fibril rocket af summari
meta-analysi studi sourc miller et al american journal
cardiolog apr show dti found least non-inferior
warfarin composit end point stroke includ hemorrhag stroke
system embol rr risk ratio reduct three drug associ
significantli decreas risk hemorrhag stroke compar warfarin rr
dabigatran rivaroxaban found compar risk major bleed
warfarin apixaban demonstr superior outcom gastrointestin
bleed heterogen new oral anticoagul associ
decreas risk intracrani bleed compar warfarin rr reduct
exhibit summari new oral anticoagul af studi vhd valvular heart diseas
novel anticoagul gener improv complianc afib still
remain signific percentag patient take medic regularli
contra-ind comorbid make stroke prophylaxi
utmost import cohort reason renew interest
device-bas therapi stroke prophylaxi especi left atrial appendag
best divid opinion clinic commun role laa
organ clinic util temptat remov laa given plethora thrombi
origin laa caus stroke obviou interest paper dr
claudia stollberg et al chest volume decemb tri highlight role
laa anatom pathophysiolog consider exhibit laa
shown two postmortem laa cast first cast laa five branch
twig dens network structur structur
approxim branch twig dens structur anatom
make-up laa signific ramif laa closur henc stroke
exhibit summari new oral anticoagul
known role laa
ventricular relax appear initi earli diastol empti laa
numer anim studi shown magnitud pattern laa
empti fill veloc depend load condit laa
veloc influenc greater extent chang left ventricular function
chang left atrial function hoit et al influenc acut alter
load condit laa flow veloc colleg cardiolog volume
sheep model laa shown mediat thirst suggest stretch
receptor laa play role mediat thirst hypovolemia zimmerman et
al intak hypovolem sheep effect crush laa scienc
human in-vivo experi laa shown reservoir function
modul relationship pressur volum experi
laa clamp led increas diastol transmitr pulmonari flow
veloc increas left atrial pressur size dog studi
distens laa shown influenc heart rate urin flow tabata
et al role left atrial appendag left atrial reservoir function evalu left
atrial appendag clamp cardiac surgeri ann journal cardiolog
guinea pig model shown intact laa result improv cardiac
output due preserv abil laa contract subsequ improv
file left ventricl compar pig ligat laa massoudi et al
influenc intact laa hemodynam paramet isol guinea pig heart
role laa endocrin organ help releas natriuret
peptid also propos especi given atrial natriuret peptid
concentr atrial tissu
given plethora evid thrombi origin laa undoubtedli
great interest find way occlud laa either epicardi endocardi
note data referenc prophylact occlus laa use
endovascular devic trial compar coumadin noac
use epicardi laa closur understand current horizon
conduct full-fledg trial henc care taken make
comparison watchman atricclip perhap interest trial
whether view posit neg protect-af trial endovascular
closur laa use watchman devic boston scientif previous
develop atritech prior call plaato devic develop
watchman three-part system consist trans-sept sheath
deliveri cathet implant nitinol devic compris self- expand nitinol
frame structur fixat barb permeabl polyest fabric cover atrial
face surfac devic
purpos report go pivot studi protect-af
watchman left atrial appendag closur laac devic embol
protect patient atrial fibril protect af trial multicent
prospect random clinic trial design demonstr watchman non-
inferior warfarin combin endpoint stroke system embol
cardiovascular unexplain death patient non-valvular af elig
warfarin therapi score total patient
center random devic vs warfarin control addit non-
random roll-in patient enrol total patient random studi
patient complet follow-up assess post-random interv day
month month month thereaft annual offic visit semi-annu
telephon visit year approxim implant subject abl
ceas warfarin day rate increas patient
baselin characterist shown exhibit next page
primari efficaci endpoint stroke ischem hemorrhag deficit
symptom persist hr symptom hr confirm ct mri
cardiovascular death limit cardiovascular unexplain death
system embol primari safeti endpoint devic embol requir
retriev pericardi effus requir intervent cranial bleed gi bleed
bleed requir unit prbc import note protect-
af design base bayesian sequenti design probabl caus lot
confus gener critic true benefit devic design
entail accru patient-year possibl maximum analyz
specif time point patient-year everi patient-year thereaft
achiev success non-inferior base first-tim success criterion met success
criterion defin probabl scale probabl
primari efficaci event rate watchman less control
probabl primari efficaci event rate watchman less control
prevail trial conform phase studi design confirm result
protect af trial valid safeti implant procedur includ
minimum random patient enrol institut particip
previou watchman studi protect af cap registri minimum
random patient enrol new oper institut total
patient random devic vs warfarin control prevail trial patient
enrol prevail warfarin-elig mean score
pre-specifi co-primari endpoint prevail trial follow
comparison composit stroke system embol cardiovascular /unexplain
death month follow-up comparison ischem stroke system
embol occur greater day post random month follow-up
earli safeti endpoint acut occurr death ischem stroke
system embol procedur devic relat complic requir open
cardiovascular surgeri major endovascular intervent devic group
prevail trial enrol patient higher risk stroke determin
differ prevail protect-af
baselin characterist prevail protect-af shown
differ prevail enrol fewer patient statist power
stand instead prevail bayesian statist design incorpor
inform prior borrow data protect-af prevail score
versu protect af averag age patient prevail
year compar year protect af moreov patient
diabet prevail vs protect af patient prior stroke
compar protect af
exhibit baselin characterist prevail vs protect-af
outcom prevail protect-af
nutshel two trial gave conflict snapshot efficaci watchman
leav investig grappl cause-effect relationship protect-af show
superior watchman coumadin howev prevail fail show non-
inferior coumadin respect outcom individu trial meta-
analysi combin cohort shown exhibit next page
exhibit order efficaci rate year meta-analysi year
protect-af result publish five year follow-up highlight
long-term data purpos report four year primari efficaci
endpoint watchman group shown superior warfarin
watchman warfarin annual demonstr rel risk reduct
composit endpoint stroke cardiovascular unexplain death
system embol posterior probabl superior note
watchman essenti undergo three round fda panel given agenc
skeptic efficaci prevail trial fda ask conduct
protect-af left doubt devic henc critic prevail post-hoc
littl misguid view prevail show laa closur meet
standard non-inferior primari efficaci endpoint stroke system embol
cardiovascular death treatment control arm rate
patient year respect secondari endpoint
ischem stroke system embol seven day post-random prevail met
statist non-inferior five year protect-af met primari endpoint due
primarili reduct incid hemorrhag stroke prevail show
reduct hemorrhag stroke rate
ischem stroke protect-af prevail diverg lead utter confus
exampl five year events/ppi protect-af increas coumadin
arm vs prevail trial subgroup analys author
state although differ rate non-dis stroke
substanti fewer disabl stroke laa closur laa closur
also associ statist signific lower rate cardiovascular unexplain
death major bleed includ bleed occur time
procedur pericardi effus vascular access complic
signific differ watchman coumadin arm trial
exclud procedure-rel event consist absent chronic oral
exhibit cardiovascular mortal protect-af year f/u
laa closur concomit surgeri
pivot studi friedman et al jama volume author conduct
retrospect cohort studi medicar patient histori afib aflutt
undergo first-tim cardiac surgeri studi evalu treatment effect
surgic laa closur vs closur laao vs no-laao baselin characterist
patient studi shown
exhibit baselin characterist surgic laa closur studi
primari outcom readmiss thromboembol stroke transient ischem
attack system embol three year follow-up defin medicar
claim data secondari end point includ hemorrhag stroke all-caus mortal
composit end point thromboembol hemorrhag stroke all-caus mortal
score underw s-laao overal mean follow-
year thromboembol occur hemorrhag stroke all-
caus mortal composit end point s-laao compar
s-laao associ lower unadjust rate thromboembol vs
all-caus mortal vs composit end point vs
signific differ rate hemorrhag stroke vs
author conclud find support use s-laao random trial
necessari provid definit evid
exhibit rate readmiss thromboembol all-caus mortal hemorrhag stroke composit endpoint
laarol electr isol also
perhap one fascin area requir investig within
space role laa closur obviou need laa closur document
numer studi resid stroke prophylaxi even though prevail
protect-af trial stroke prophylaxi gave conflict result notion
elimin area stasi fibril atrium prevent thromboembol make
sens unclear though laa closur role whatsoev electr
isol arrhythmogen foci therefor potenti ad increment benefit
freedom af burden
studi panikk et al circul arrhythmia electrophysiolog volume laa
electr isol occlus attempt patient long-stand persist
af outcom compar balanc ratio control group af
ablat alon among patient underw ablat laa electr isol
possibl nineteen twenti patient stop warfarin month without
antiarrhythm drug freedom af month singl procedur
significantli higher studi group control group
freedom atrial arrhythmia demonstr
patient procedur mean respect
exhibit freedom af burden month electr isol laa
anoth larg registri circul volume author natal et al evalu
role laa isol consecut patient paroxysm non-paroxysm
undergo redo cathet ablat af hundr sixty-six patient show
fire laa becam studi popul patient
paroxysm non-paroxysm laa found sourc arrhythmia
pulmonari vein extra-pulmonari vein site reconnect ablat
perform either focal lesion group achiev laa isol placement
circular cathet ostium laa guid intracardiac echocardiographi
patient group remain patient laa fire ablat group
follow-up patient group recurr compar
group group
exhibit freedom af burden natal registri
current conduct pivot studi call deep-af stage deep-af
single-arm open-label studi design studi safeti
effect dual epicardi endocardi ablat procedur patient
present persist atrial fibril long-standing persist atrial fibril
util atricur bipolar atriclip laa exclus
endoscop open ablat procedur follow endocardi map
ablat cathet endocardi lesion us ou site expect
enrol patient studi durat follow-up five year inclus
criteria patient year age younger time
consent symptomat palpit short breath fatigu persist atrial
fibril long-standing persist atrial fibril refractori minimum one class
class aad exclus criteria patient document histori af
year patient ep cathet ablat procedur treat atrial
fibril within month prior sign consent primari efficaci endpoint
freedom document af atrial flutter atrial tachycardia last
second durat follow-up visit absenc class
aad except previous fail aad dose exceed
previous fail primari safeti endpoint freedom major advers
event mae adjud clinic event committe cec relat
atricur bipolar atriclip laa exclus within day
epicardi surgic ablat procedur within day index endocardi
procedur within day repeat endocardi procedur within blank
period latest enrol statu suffic say current
coronaviru pandem bound delay trial
converg superior studi compar epicardi endocardi ablat vs
endocardi ablat random studi multi-cent prospect open
label random studi design evalu safeti efficaci
converg procedur use ncontact epi-sense-af guid coagul
irrig cathet af ablat treat symptomat persist af patient refractori
intoler least one class and/or aad compar endocardi cathet
ablat alon approxim patient site us ou enrol
studi follow-up extend five year inclus criteria patient
age year less year la refractori intoler one
aad class and/or document persist af exclus criteria
patient requir concomit surgeri valvular repair replac cabg
surgeri atrial septal defect closur patient previou left atrial
cathet ablat af includ ablat supraventricular
primari efficaci endpoint success failur af/at/afl free absent class
aad except previous fail intoler class aad increas
dosag follow three-month blank period month post
procedur follow-up visit primari safeti endpoint studi freedom
mae adjud cec procedur day post procedur time
period complet enrol studi august last patient follow-
complet top-lin result studi present
late break session heart rhythm societi meet may
thing note converg trial
protocol call prior cathet ablat either arm trial
approv irrig rf cathet use trial includ forc
sens two use trial thermocool st jude/abt endocardi
ablat done epicardi ablat
electroanatom map insid heart becom easier epicardi
lesion set creat includ pv isol rooflin epicardi
lesion set specif includ back wall lesion one critic aspect
use epicardi ablat first back wall ablat
avoid excess heat creat esophag fistula
endpoint measur use holter meter measur af
converg follow heart rhythm societi hr guidelin fda
negoti protocol endpoint measur sure question
rais durat measur constitut proper window
amaz superior trial design evalu safeti effect lariat
percutan isol ligat left atrial appendag treatment
persist long-standing persist af studi conduct two stage
limit earli stage stage subject site pivot stage/
phase stage subject site subject stage
includ primari analysi complet enrol second stage
decemb follow-up on-going pma submiss expect later
pma expect primari endpoint trial freedom
episod atrial fibril second month post index pulmonari
vein isol measur holter monitor note amaz key
focu report sinc convinc lariat devic util vi -- vi
key dynam cite tailwind updat hr consensu
guidelin surgic af ablat deep dive cathet ablat base
chang simpli provid birds-ey view surgic af ablat chang
potenti affect time highlight key question
still rais consensu document consist overal view af
exhibit updat guidelin surgic af ablat
unansw question af ablat
direct cut past hr consensu statement essenti
summar question confound proper understand diseas state
treatment approach note consensu statement develop
expert around world henc comment reflect heavili space gener
af ablat modif stroke risk need on-going oral anticoagul
oac score develop patient clinic af patient
receiv success ablat he/sh longer clinic af subclin
af need on-going oac patient
success ablat could lead discontinu oac
substrat modif catheter-bas manag afparticularli persist af
proper lesion set requir beyond pulmonari vein isol line
complex fraction atrial electrogram cfae remain role
approach ill-advis simpli discourag role target local
rotat activ ablat local rotat activ scar
character target ablat need replic maze procedur
right atrium need target well left atrium
autonom influenc af clinic af realli autonom mediat arrhythmia
elimin ganglion plexi requir role autonom modul
exampl spinal cord vagal stimul
contribut modul risk factor outcom af ablat obes reduct
shown reduc af burden recurr patient undergo ablat
role bariatr surgeri modul risk factor influenc outcom
hypertens sleep apnea diabet
outcom ablat high-risk popul high-risk popul benefit af
ablat congest heart failur assess smaller trial larger trial
requir outcom data need patient enlarg la hypertroph
cardiomyopathi patient renal failur dialysi elderli
surgic vs catheter-bas vs hybrid ablat compar work
percutan minim invas surgic approach report similar
outcom dearth compar data patient benefit hybrid
character patient optim candid ablat preablat late
gadolinium-enhanc lge -magnet reson imag mri might identifi patient
heavi burden scar unlik respond ablat techniqu must
becom reproduc reliabl must assess multicent trial
marker need investig includ genet marker biochem marker
clinic marker base aggreg risk score
increment role new technolog newer often expens
technolog produc af ablat definit increment valu must
determin order justifi chang practic case cost technolog includ
global basket map techniqu newer ablat indic assess lesion durabl
advanc imag view lesion myocardium etc new energi sourc
mri-guid ablat must assess compar fashion
outcom af ablat need better understand clinic relev ablat
outcom signific time recurr second arrhythmia
best quantifi af burden outcom relat qualiti life stroke
role surgic la reduct left atrial appendag laa occlus
obliter improv outcom persist af ablat accompani reduct
stroke ablat work atrial size reduct incid stiff
atrial syndrom mitig clinic impact ablat
work team role entir heart team af ablat team
approach achiev better outcom silo approach
improv safeti cathet ablat ablat extend oper less
experienc oper statist occurr complic increas need
newer techniqu minim complic institut standard oper
improv reproduc ablat result safeti profil varieti center
cathet ablat affect mortal stroke hospit broad
select patient popul receiv cathet ablat af
manag patient fail initi attempt cathet ablat
specif criteria repeat ablat atrial size bodi mass index patient
refer surgeri repeat ablat
reimburs surgic af ablat well establish lucr
inpati set reimburs hybrid ablat though mix bag
stage current two separ code use epicardi endocardi
procedur done day epicardi code use
key competitor surgic af ablat side boast
rang product cardiobl irrig surgic rf ablat pen
cardiobl map tool cardiobl cryoflex cryoablat probe clamp
best guesstim us market share concomit af
around share ou seem
greater market share concomit af detail stand-alon minim
invas hybrid af ablat market share avail us especi sinc
mish-mash data cathet use endocardi ablat type
tool energi deliveri devic use per case etc
past five year good growth trajectori
organ as-report basi overal revenu increas roughli
compound-annual-growth-rate octob
complet acquisit ncontact surgic base north carolina ncontact
time acquisit contribut annual sale sale
repres hand late compani acquir estech surgic af
compani base california recent compani acquir sentreheart
develop lariat endocardi epicardi laa closur devic approxim
contribut variou busi segment shown exhibit exit
biggest contributor growth atrclip laa closur devic growth
rang second open af ablat growth us
revenu constitut overal revenu grow y/i ou revenu
exit grow
quarterli revenu trajectori profil shown growth prospect
closer analysi growth prospect within individu busi segment
atriclip flagship product left atrial appendag closur current
wit rapid growth us grow awar pathogenesi thrombi
laa origin embol stroke laa combin societi guidelin
encourag closur laa appropri fuel interest atriclip
note unlik watchman devic atriclip indic prophylact use
henc care taken triangul overal base asp
estim atriclip use roughli
procedur worldwide/year remain unclear though aggreg revenu
per case abl deriv use product af ablat nerv block
atriclip
exhibit order gross margin opex sale
gross margin roughli rang rel minor fx
headwind compar affect larger med-tech compani long-
term gross margin creep rang believ margin roughli
remain flattish next two three year especi given full-year
absorpt sentreheart oper probabl key driver valu
name least long-term basi remain abil squeez opex
synergi current opex account roughli sale therefor crimp
leverag model expect expens sale
sg sale increas invest reflect full year amaz trial
cost includ continu access protocol continu invest ice-afib
deep af trial converg pma cost continu access protocol new
clinic scienc activ along pipelin develop increas sg
driven expans world-wide sale team particularli ep-focus team
cryo nerv block team addit import invest train
market activ continu leverag
marginsg
model aggreg growth rate y/i
respect compani guidanc revenu rang
y/i howev drastic lower compani guidanc
field check overal lend comfort short-term outlook procedur
volum henc deliber conserv
consensu revert back normal growth rate scenario
number believ converg trial result probabl key
driver stock perform next month per compani commentari
hybrid af ablat done/year us thu
depend converg result shape reimburs work
feel stand-alon hybrid af ablat could provid boost need minim
invas surgeri mi line item model indic compani
break-even next three year
michael carrel serv presid ceo sinc novemb
join mr carrel presid chief execut offic vital
imag publicly-trad medic imag softwar compani led vital imag
global leadership posit healthcar medic softwar industri
leadership compani grew revenu profit increas global market share
expand presenc countri lead compani sale
toshiba medic system corpor prior join vital imag mike presid
ceo zamba corp publicly-trad technolog compani chief
offic nextnet wireless privately-held provid non-line-of-sight plug play
broadband wireless access system mr carrel serv board medic devic
manufactur associ mdma inc
earn account pennsylvania state univers
wharton school univers pennsylvania
andi wade serv chief offic sinc januari
join held varieti progress financ
leadership posit prior join mr wade held financi posit
maci inc sak inc mr wade start career arthur andersen llp
audit practic serv client variou industri current serv board
american heart associ chapter cincinnati mr wade receiv
account xavier univers master busi administr owen
school vanderbilt univers certifi public account
initi coverag outperform rate
price target pt deriv use multipl sale estim
repres strong pure-play surgic af marketplac
concomit left atrial appendag closur continu key driver stori
converg trial data readout hr confer may present posit
catalyst stori view alreadi telegraph posit outcom
converg question remain answer increment benefit
epicardi ablat endocardi ablat logist challeng
increment econom work end stori continu chug along
clip next year driven larg preval pool continu
accept surgic af ablat stand-alon concomit especi light
hr guidelin enthus amaz studi
sentreheart acquisit henc factor either analysi sure
current pandem dampen procedur volum extent long-
term view attract pure play tough-to-treat diseas segment
henc begin coverag outperform rate target
exhibit forward price/sal vs small-cap univers
oppenheim co factset estim
reimburs surgic af ablat lucr well-establish howev
reimburs hybrid surgic af ablat establish singl code
industri tackl converg result publish interest
converg repres signific mileston compani histori
determin larg extent growth trajectori move forward
current pandem creat widespread uncertainti outlook
despit surgeri deferr guidelin rel benign toward
procedur admittedli wide variat procedur depend
statement oper
number mm except per share
sale
sg
equival
current liabil current matur debt leas
long-term debt net discount current
conting consider
accumul comprehens incom loss
stock price compani mention report
